Lipedema Diagnosis

Biomarkers for Lipedema

Biomarker research in lipedema has identified distinct metabolic, inflammatory, and tissue-based signatures that differentiate this condition from obesity and lymphedema. Though no single validated diagnostic biomarker currently exists, in the future they may serve to aid in diagnostic, staging, and predictors of progression.

Metabolic Biomarkers

Lower levels of histidine and phenylalanine, combined with elevated pyruvic acid, distinguish lipedema from obesity, with pyruvic acid showing particularly strong diagnostic potential. [1] Additional metabolomic changes include altered circulating glutamic acid, glutathione, and sphingolipid levels.[2] Despite these metabolic differences, lipidomic analysis of adipose tissue and serum shows no significant changes in lipid composition compared to BMI-matched controls.[3]

Glucose Metabolism

Lipedema patients demonstrate better glucose metabolism than BMI-matched controls, with lower HbA1c (5.55% vs 6.73%) and higher adiponectin levels (4.69 vs 3.28 mmol/L).[4] However, they paradoxically show higher total cholesterol and LDL-C levels.[4] The prevalence of glucose metabolism alterations increases progressively with clinical stage, reaching 34% overall in an Italy-based observational study where studies estimate 39.9% of the general population has prediabetes under ADA criteria.[5] For reference, according to the CDC the general US adult prevalence of prediabetes is 38% using data from 2017-2020.

Inflammatory and Cytokine Markers

Systemic cytokine profiles distinguish lipedema from other conditions including elevated serum levels of IL-11, IL-28A, and IL-29.[3] Increased VEGF-C levels (without corresponding lymphatic vessel morphological changes) and elevated inflammatory markers including TNFSF14, CASP8, EN-RAGE, EIF4EBP1, ADA, and MCP-1 are present.[4][6] C-reactive protein levels increase with clinical stage severity.[5] 

Notably, the inflammatory profile differs from obesity, showing M2 macrophage predominance rather than the pro-inflammatory M1 response typical of obesity.[7-8]

Tissue-Based Biomarkers

Tissue sodium content measured by MRI is elevated in both skin (14.9 vs 11.9 mmol/L) and subcutaneous adipose tissue (11.9 vs 9.4 mmol/L) in lipedema patients compared to controls, potentially providing an objective imaging-based biomarker. Skin sodium content correlates directly with fat-to-water volume ratio.[9]

Gene expression analysis reveals downregulation of Tie2 and FLT4 (VEGFR-3), along with decreased local VEGF-A and VEGF-D expression.[6] Adipose-derived stem cells from lipedema tissue show impaired adipogenesis with reduced adiponectin and leptin production, differing in insulin-like growth factor-1, aromatase (CYP19A1), and interleukin-8 expression.[10]

Clinical Implications

Using a combination of these biomarkers shows promise for disease prediction models.[2] However, no specific biomarker has yet been validated for routine clinical diagnosis, which remains based on clinical criteria.[11] Research continues to focus on developing precision medicine approaches and standardized diagnostic criteria.[9]

Sources

  1. Serum Metabolomic Profiling of Patients With Lipedema. Kempa S, Buechler C, Föh B, et al. International Journal of Molecular Sciences. 2023;24(24):17437. doi:10.3390/ijms242417437.
  2. Defining Lipedema’s Molecular Hallmarks by Multi-Omics Approach for Disease Prediction in Women. Straub LG, Funcke JB, Joffin N, et al. Metabolism: Clinical and Experimental. 2025;168:156191. doi:10.1016/j.metabol.2025.156191.
  3. A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status Without Significant Changes in the Lipid Composition Characterizes Lipedema. Wolf S, Deuel JW, Hollmén M, et al. International Journal of Molecular Sciences. 2021;22(7):3313. doi:10.3390/ijms22073313.
  4. Is Subcutaneous Adipose Tissue Expansion in People Living With Lipedema Healthier and Reflected by Circulating Parameters?. Nankam PAN, Cornely M, Klöting N, Blüher M.Frontiers in Endocrinology. 2022;13:1000094. doi:10.3389/fendo.2022.1000094.
  5. Observational Study on a Large Italian Population With Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History. Patton L, Ricolfi L, Bortolon M, et al. International Journal of Molecular Sciences. 2024;25(3):1599. doi:10.3390/ijms25031599.
  6. Increased Levels of VEGF-C and Macrophage Infiltration in Lipedema Patients Without Changes in Lymphatic Vascular Morphology. Felmerer G, Stylianaki A, Hollmén M, et al. Scientific Reports. 2020;10(1):10947. doi:10.1038/s41598-020-67987-3.
  7. Lipedema and Adipose Tissue: Current Understanding, Controversies, and Future Directions. Rabiee A. Frontiers in Cell and Developmental Biology. 2025;13:1691161. doi:10.3389/fcell.2025.1691161.
  8. Adipose Tissue Hypertrophy, an Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema. Felmerer G, Stylianaki A, Hägerling R, et al. The Journal of Surgical Research. 2020;253:294-303. doi:10.1016/j.jss.2020.03.055.
  9. Tissue Sodium Content Is Elevated in the Skin and Subcutaneous Adipose Tissue in Women With Lipedema. Crescenzi R, Marton A, Donahue PMC, et al. Obesity (Silver Spring, Md.). 2018;26(2):310-317. doi:10.1002/oby.22090.
  10. Adipose Stem Cells From Lipedema and Control Adipose Tissue Respond Differently to Adipogenic Stimulation in Vitro. Bauer AT, von Lukowicz D, Lossagk K, et al. Plastic and Reconstructive Surgery. 2019;144(3):623-632. doi:10.1097/PRS.0000000000005918.
  11. Lipedema-Pathogenesis, Diagnosis, and Treatment Options. Kruppa P, Georgiou I, Biermann N, et al. Deutsches Arzteblatt International. 2020;117(22-23):396-403. doi:10.3238/arztebl.2020.0396.
Share